CoChat
Sign Up
Cited by 212Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsBlood Pressure and Hypertension Studies

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias

Davies, Neil M., Kehoe, Patrick G, Ben-Shlomo, Yoav, Martin, Richard M.·2011·Journal of Alzheimer’s Disease
DOI 10.3233/jad-2011-110347
Open this paper in CoChat — free account

Abstract

We investigated whether angiotensin II receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACE-Is) are more strongly associated with Alzheimer's disease (AD), vascular dementia (VaD), and other dementias, than other anti-hypertensive drugs. We conducted a nested case-control analysis within the UK general practice research database, with prospectively recorded anti-hypertensive prescribing data. We sampled cases aged ≥60 years and diagnosed between 1997–2008 (5,797 with AD, 2,186 with VaD, 1,214 with unspecified/other dementia) which were matched to up to four controls by age, general practice and gender. We computed odds-ratios and dose response effects for AD, vascular and unspecified/other dementia, comparing those prescribed ARBs or ACE-Is for at least six months with patients prescribed other anti-hypertensives. We controlled for matching factors, co-morbidities, smoking status, an area measure of socioeconomic status, consultation rate and blood pressure and accounted for reverse causality by introducing time-lags of up to eight years prior to diagnosis/index date. Patients diagnosed with AD, vascular and unspecified/other dementia had fewer prescriptions for ARBs and ACE-Is. Inverse associations with AD were strongest for ARBs (odds-ratio; 0.47, 95%CI, 0.37–0.58) compared with ACE-Is (odds-ratio; 0.76, 95%CI, 0.69–0.84) (p difference < 0.001). Associations of ARBs with AD were stronger than for vascular dementia (p difference = 0.01) and unspecified/other dementia (p difference = 0.23). There were inverse dose-response relationships between ARBs and ACE-Is with AD (both p trend < 0.01). The inverse association of ACE-Is with AD diminished when using longer time lags but the ARB-AD association persisted. Patients with AD were around half as likely to be prescribed ARBs. Further randomized controlled trial evidence is required to rigorously test these findings.

Overview

Integrity signals

Registry

Crossref · 10.3233/jad-2011-110347

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

Sorted by citations

Items 201–212 of 212

Related

See all

Metadata

Authors
Davies, N. M., Kehoe, P. G., Ben-Shlomo, Y., & Martin, R. M.
Affiliations
  • University of Bristol (GB)
  • Frenchay Hospital (GB)
  • School of Social and Community Medicine, Faculty of Medicine and Dentistry, University of Bristol, Canynge Hall, Bristol, UK
Corresponding author
Kehoe, Patrick G
ORCID
Venue
Journal of Alzheimer’s Disease
Publisher
SAGE Publications
Published
2011-10-04
Volume
26
Issue
4
Pages
699-708
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
DOI
10.3233/jad-2011-110347
OpenAlex
W1828947725
Cited by
212
References
41
Citations by year
2026: 3 · 2025: 3 · 2024: 12 · 2023: 9 · 2022: 9 · 2021: 16 · 2020: 17 · 2019: 8 · 2018: 14 · 2017: 12 · 2016: 28 · 2015: 15 · 2014: 18 · 2013: 24 · 2012: 19
FWCI
14.44
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Alzheimer s Disease (publishedVersion)
  • PubMed (publishedVersion)
  • Explore Bristol Research (publishedVersion)
  • Bristol Research (University of Bristol) (submittedVersion)
Funders
  • North Bristol NHS Trust
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
angiotensin receptor blockers, ACE inhibitors
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Blood Pressure, Data Interpretation, Statistical, Dementia, Dose-Response Relationship, Drug, Female, United Kingdom, Humans, Male, Socioeconomic Factors, Dementia, Vascular, Case-Control Studies, Databases, Factual, Angiotensin II Type 1 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review